Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of first-in-class small-molecule and protein therapeutics. The company focuses on addressing significant unmet medical needs across large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Headquartered in Seattle, Washington, Omeros aims to transform patient care through groundbreaking science and innovative drug development.

Omeros's key product is YARTEMLEA® (narsoplimab-wuug), an FDA-approved and commercially available treatment in the U.S. for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. The company's diverse pipeline includes OMS1029, a long-acting MASP-2 inhibitor; OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder and other addictions; and OMS906, a MASP-3 inhibitor targeting paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Omeros also maintains preclinical programs for novel recombinant antibodies in oncology and for multidrug-resistant organisms.

In recent developments, YARTEMLEA® was launched in the U.S. market in January 2026, generating $11.1 million in gross product sales during the first quarter of 2026. However, on June 26, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Marketing Authorization Application for narsoplimab in TA-TMA, a decision Omeros intends to appeal. The company is led by Gregory A. Demopulos, M.D., who serves as President, Chief Executive Officer, and Chairman of the Board. Omeros is strategically positioned as a commercial-stage biopharmaceutical company, concentrating on a select portfolio of high-value biologic programs.